The US cleared cultivated meat — then cost, scale and state bans, not regulation, became the wall
In June 2023 UPSIDE Foods completed all three US steps to sell cell-cultivated chicken — FDA "No Questions" (Nov 2022), USDA-FSIS label approval and Grant of Inspection (company announcement, 21 Jun 2023). By 2026 five firms hold clearances, yet product is essentially absent from shelves — limited to restaurant tests — because of cost and scale, while seven states (e.g., Florida, Texas) enacted bans now in litigation. A textbook "atoms are the bottleneck" signal.
UPSIDE Foods completed the US regulatory triple — FDA "No Questions" letter (Nov 2022), USDA-FSIS label approval and a Grant of Inspection (June 2023) — making cell-cultivated chicken legally sellable for the first time. The company's own announcement is the primary record; the underlying government actions are the FDA pre-market consultation and the FSIS grant it describes.
Live status (checked 2026-06-27): five firms (UPSIDE, GOOD Meat, Wildtype salmon, Mission Barns, Believer) now hold clearances, but product is essentially absent from retail — limited restaurant tests — reflecting cost and scale, not regulatory barriers. Seven states enacted bans; a federal appeals court upheld Florida's ban in March 2026 (litigation ongoing).
Why it matters (spine): the bottleneck is physical (bioreactor throughput, media cost, cell density), exactly P3 — and the cross-garden read spans CulKG, FshKG (cell-based seafood) and HKG.
Falsifier: the GOI never held, or cost-competitive retail scale arrives before 2030. · Confidence: 0.9.
So we should back the cost/scale problem and treat state-ban litigation as the binding near-term risk.
Bet on the scale-up / cost-per-pound problem (bioreactors, media cost, cell density) — atoms, not rules — and watch the state-ban litigation as the real near-term risk.
domains: cultivated-meat · food · scale-up · regulation · bioreactors